抗感染症薬の世界市場規模：薬剤タイプ別、適応症別、流通チャネル別、地域範囲別および予測

抗感染症薬の市場規模と予測

抗感染症薬の市場規模は、2024年に1,387億7,000万米ドルと評価され、2026年から2032年にかけてCAGR 5.05%で成長し、2032年には2,058億1,000万米ドルに達すると予測されます。

市場拡大に拍車をかけている重要な要素は、インフルエンザの流行増加です。伝染性のウイルスであるインフルエンザは、軽度から中等度の症状だけでなく、死亡を含む重篤な合併症を引き起こす可能性があります。本レポートは、世界の抗感染症薬市場を総合的に評価したものです。本レポートは、様々なセグメントと、市場で重要な役割を果たしている動向や要因の分析から構成されています。

世界の抗感染症薬市場の定義

世界保健機関（WHO）が認識している世界の健康負荷の主要なもの1つが感染症です。感染症は、細菌感染、真菌感染、ウイルス感染など、さまざまな病原体によって引き起こされる致死性の病気です。抗感染症薬は、多くの原因によって引き起こされる感染症を治療するために一般的に使用される治療法です。抗感染薬は、感染症の原因となる生物を排除したり、さまざまな毒素を放出することで宿主の複製や感染を阻止したりするために使用されます。

感染症を引き起こす微生物には、細菌、ウイルス、真菌、ウイルス、微小寄生虫などがあります。感染症は、その原因となる微生物の種類や患者の病気の徴候や症状によって分類されます。今日、地球全体が直面している最も重大な健康問題のひとつが感染症です。感染症は、細菌感染、真菌感染、ウイルス感染など、多くの病原体によって引き起こされる致死的な病気です。感染症は急速に蔓延し、抗感染症薬は真菌、細菌、ウイルス、その他の病原体を含む多種多様な微生物種の治療に使用されます。

抗感染症薬は、様々な原因によって引き起こされる感染症を治療するために一般的に使用される治療法です。抗感染症薬は、DNAの産生を阻害したり、感染拡大を阻止するために細胞成分を破壊したりするなど、いくつかの方法で機能します。抗感染症薬市場には、微生物疾患を治療するためのブランドまたはジェネリックの抗感染症薬、および関連製品やサービスを製造する事業体（組織、個人事業主、パートナーシップ）が参入しています。

世界の抗感染症薬市場概要

ヒト免疫不全ウイルス（HIV）が免疫系にダメージを与える結果、ヒトはますます感染症にかかりやすくなっています。HIVが適時に治療されない場合、後天性免疫不全症候群（AIDS）が発症する可能性があります。国連合同エイズ計画（UNAIDS）によると、2020年だけでも世界で約150万人がHIVに感染しています。HIVは白血球として知られるCD4細胞に害を及ぼし、死滅させます。これは、病気と闘う身体の能力を妨げます。抗ウイルス薬はウイルスの増殖を防ぎ、体内のHIVレベルを下げ、免疫系の細胞生産を再活性化します。市場の拡大に拍車をかけているもう一つの重要な要素は、インフルエンザの流行の増加です。伝染性のウイルスであるインフルエンザは、軽度から中等度の症状だけでなく、死亡を含む重篤な合併症を引き起こす可能性があります。

抗感染症薬産業の拡大は、2018～2019年に3,550万人がインフルエンザに罹患し、49万600人が入院、3万4,200人が死亡したと疾病管理予防センター（CDC）が報告していることが後押ししています。抗感染症薬市場は、骨髄や臓器オンチップ（OOC）技術など、最近の創薬手法の進歩から恩恵を受けると予想されます。OOCは、臓器系の運動、動き、生理的反応を再現するために綿密に構築された生体認証システムです。標的の同定、検証、スクリーニングは、OOCや幹細胞技術を用いた臨床試験手順の一例です。これらの技術は、医薬品開発にかかる費用を削減し、医薬品の効能やヒトに対する安全性の信頼性の高い予測を提供しています。

しかし、市場開拓は、研究開発コストの高さやヘルスケア施設のリソース不足によって制約を受ける可能性があります。しかし、世界保健機関（WHO）は、2030年までに6人に1人が60歳以上になり、2050年までに世界の60歳以上の人口は21億人に倍増すると予測しています。80歳以上の人口は2020年から2050年の間に3倍に増え、4億2,600万人に達すると予想されています。加齢に伴う免疫システムの劣化は、病気と闘い、予防接種に反応する身体の能力を低下させます。免疫系は自己病原体と外来病原体を見分ける能力が低下します。過去に出会った抗原の記憶を保持するT細胞は、新規抗原に対する反応が鈍くなります。併存疾患の増加と免疫系の活性低下により、人々は感染症にかかりやすくなっており、これが市場の成長をもたらしています。

目次

第1章 世界の抗感染症薬市場の導入

• 市場の定義
• 市場セグメンテーション
• 調査スケジュール
• 前提条件
• 制限事項

第2章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• データの三角測量
• ボトムアップアプローチ
• トップダウンアプローチ
• 調査の流れ
• 業界専門家による主要な洞察
• データソース

第3章 エグゼクティブサマリー

• 市場概要
• エコロジーのマッピング
• 絶対的収益機会
• 市場の魅力
• 抗感染症薬の世界市場地域別分析（CAGR %）
• 抗感染症薬の世界市場：薬剤タイプ別
• 抗感染症薬の世界市場：適応症別
• 抗感染症薬の世界市場：流通チャネル別
• 今後の市場機会
• 世界市場分割
• 製品ライフライン

第4章 抗感染症薬の世界市場展望

• 世界の抗感染症薬の進化
• 促進要因
  • 促進要因1
  • 促進要因2
• 抑制要因
  • 抑制要因1
  • 抑制要因2
• 機会
  • 機会1
  • 機会2
• ポーターのファイブフォースモデル
• バリューチェーン分析
• 価格分析
• マクロ経済分析

抗感染症薬の世界市場、薬剤タイプ別

• 概要
• 抗生物質
• 抗ウイルス剤
• 抗真菌薬

第5章 抗感染症薬の世界市場：適応症別

• 概要
• HIV
• 肺炎
• 呼吸器感染症
• 結核
• その他

第6章 抗感染症薬の世界市場：流通チャネル別

• 概要
• 病院薬局
• 小売薬局
• その他

第7章 抗感染症薬の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
  • その他ラテンアメリカ
• 中東・アフリカ
  • アラブ首長国連邦
  • サウジアラビア
  • 南アフリカ
  • その他中東とアフリカ

第8章 世界の抗感染症薬市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な発展
• 企業の地域別フットプリント
• 企業の産業別フットプリント
• ACEマトリックス

第9章 企業プロファイル

• Novartis AG
• Merck & Co., Inc
• Alcon Pharmaceuticals Ltd
• Quest Diagnostics Inc.
• AstraZeneca Plc
• Anofi SA
• GSK
• Gilead Sciences
• Novartis AG
• Cipla

第10章 VERIFIED MARKET INTELLIGENCE

• VERIFIED MARKET INTELLIGENCEについて
• ダイナミックなデータの可視化

LIST OF TABLES

TABLE1 Global Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 2 Global Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 3 Global Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 4 Global Anti Infective Drugs Market, By Geography, 2022 - 2030 (USD Billion)

TABLE 5 North America Anti Infective Drugs Market, By Country, 2022 - 2030 (USD Billion)

TABLE 6 North America Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 7 North America Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 8 North America Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 9 US Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE10 US Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE11 US Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE12 Canada Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE13 Canada Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE14 Canada Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE15 Mexico Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE16 Mexico Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE17 Mexico Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE18 Europe Anti Infective Drugs Market, By Country, 2022 - 2030 (USD Billion)

TABLE19 Europe Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 20 Europe Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 21 Europe Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 22 Germany Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 23 Germany Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 24 Germany Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 25 UK Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 26 UK Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 27 UK Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 28 France Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 29 France Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 30 France Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 31 Rest of Europe Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 32 Rest of Europe Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 33 Rest of Europe Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 34 Asia-Pacific Anti Infective Drugs Market, By Country, 2022 - 2030 (USD Billion)

TABLE 35 Asia-Pacific Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 36 Asia-Pacific Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 37 Asia-Pacific Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 38 China Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 39 China Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 40 China Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 41 Japan Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 42 Japan Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 43 Japan Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 44 India Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 45 India Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 46 India Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 47 Rest of Asia-Pacific Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 48 Rest of Asia-Pacific Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 49 Rest of Asia-Pacific Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 50 RoW Anti Infective Drugs Market, By Country, 2022 - 2030 (USD Billion)

TABLE 51 RoW Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 52 RoW Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 53 RoW Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 54 Middle East and Africa Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 55 Middle East and Africa Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 56 Middle East and Africa Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

TABLE 57 Latin America Anti Infective Drugs Market, By Drug Type , 2022 - 2030 (USD Billion)

TABLE 58 Latin America Anti Infective Drugs Market, By Indication, 2022 - 2030 (USD Billion)

TABLE 59 Latin America Anti Infective Drugs Market, By Distribution Channel, 2022 - 2030 (USD Billion)

• TABLE 60 Novartis AG: Product Benchmarking
• TABLE 61 Novartis AG: Key Development
• TABLE 62 Merck & Co., Inc: Product Benchmarking
• TABLE 63 Merck & Co., Inc: Key Development
• TABLE 64 Alcon Pharmaceuticals Ltd: Product Benchmarking
• TABLE 65 Alcon Pharmaceuticals Ltd: Key Development
• TABLE 66 Alcon Pharmaceuticals Ltd: Product Benchmarking
• TABLE 67 Alcon Pharmaceuticals Ltd: Key Development
• TABLE 68 Quest Diagnostics Inc.: Product Benchmarking
• TABLE 69 Quest Diagnostics Inc.: Key Development
• TABLE 70 AstraZeneca Plc: Product Benchmarking
• TABLE 71 AstraZeneca Plc: Key Development
• TABLE 72 Anofi SA: Product Benchmarking
• TABLE 73 Anofi SA: Key Development
• TABLE 74 GSK: Product Benchmarking
• TABLE 75 GSK: Key Development
• TABLE 76 Gilead Sciences: Product Benchmarking
• TABLE 77 Gilead Sciences: Key Development
• TABLE 78 Novartis AG: Product Benchmarking
• TABLE 79 Novartis AG: Key Development
• TABLE 80 Cipla: Product Benchmarking
• TABLE 81 Cipla: Key Development

LIST OF FIGURES

• FIGURE1 Global Anti Infective Drugs Market Segmentation
• FIGURE 2 Research Timelines
• FIGURE 3 Data Triangulation
• FIGURE 4 Market Research Flow
• FIGURE 5 Data Sources
• FIGURE 6 Global Anti Infective Drugs Market Overview
• FIGURE 7 Global Anti Infective Drugs Market Geographical Analysis, 2022-2030

FIGURE 8 Global Anti Infective Drugs Market, By Drug Type (USD Million)

FIGURE 9 Global Anti Infective Drugs Market, By Indication (USD Million)

FIGURE10 Global Anti Infective Drugs Market, By Distribution Channel (USD Million)

• FIGURE11 Future Market Opportunities
• FIGURE12 Porters Five Force Model
• FIGURE13 COVID-19 Analysis
• FIGURE14 Global Anti Infective Drugs Market Geographical Analysis, 2022-2030

FIGURE15 Global Anti Infective Drugs Market, By Drug Type (USD Million)

FIGURE16 Global Anti Infective Drugs Market, By Indication (USD Million)

FIGURE17 Global Anti Infective Drugs Market, By Distribution Channel (USD Million)

• FIGURE18 North America Snapshot
• FIGURE19 North America Anti Infective Drugs Market Share, By Country, 2022
• FIGURE 20 Europe Snapshot
• FIGURE 21 Europe Anti Infective Drugs Market Share, By Country, 2022
• FIGURE 22 Asia-Pacific Snapshot
• FIGURE 23 Asia-Pacific Anti Infective Drugs Market Share, By Country, 2022
• FIGURE 24 RoW Snapshot
• FIGURE 25 RoW Anti Infective Drugs Market Share, By Country, 2022
• FIGURE 26 Key Strategic Developments
• FIGURE 27 Novartis AG Company Insight
• FIGURE 28 SWOT Analysis: Novartis AG
• FIGURE 29 Merck & Co., Inc Company Insight
• FIGURE 30 SWOT Analysis: Merck & Co., Inc
• FIGURE 31 Alcon Pharmaceuticals Ltd Company Insight
• FIGURE 32 SWOT Analysis: Alcon Pharmaceuticals Ltd
• FIGURE 33 Quest Diagnostics Inc. Company Insight
• FIGURE 34 AstraZeneca Plc Company Insight
• FIGURE 35 Anofi SA Company Insight
• FIGURE 36 GSK Company Insight
• FIGURE 37 Gilead Sciences Company Insight
• FIGURE 38 Novartis AG Company Insight

Anti Infective Drugs Market Size And Forecast

Anti Infective Drugs Market size was valued at USD 138.77 Billion in 2024 and is projected to reach USD 205.81 Billion by 2032, growing at a CAGR of 5.05% from 2026 to 2032

An important element fueling the market's expansion is the rise in the prevalence of influenza. A contagious virus, influenza can result in both mild to moderate symptoms and serious complications, including death. The Global Anti Infective Drugs Market report provides a holistic evaluation of the market. The report comprises various segments as well as an analysis of the trends and factors that are playing a substantial role in the market.

Global Anti Infective Drugs Market Definition

One of the major global health burdens recognised by the World Health Organisation (WHO) is infectious illnesses. It is a potentially lethal illness brought on by a number of pathogens, such as bacterial, fungal, and viral infections. Anti-infectives are a form of therapy commonly used to treat infections brought on by a number of causes. Anti-infective drugs are used to eliminate infection-causing organisms or stop them from replicating or infecting the host by releasing a variety of toxins.

Microorganisms that cause infections include bacteria, viruses, fungi, viruses, and microparasites. Infections are categorised according to the type of organism that causes them as well as the patient's signs and symptoms of illness. One of the most significant health issues facing the entire globe today is infectious diseases. It is a potentially lethal illness brought on by a number of pathogens, including bacterial, fungal, and viral infections. Infectious diseases spread swiftly, and anti-infective drugs are used to treat a wide variety of microbiological species, including fungi, bacteria, viruses, and other pathogens.

Anti-infectives are a form of therapy commonly used to treat infections brought on by a number of causes. Anti-infective drugs function in several ways, such as by blocking DNA production and/or by destroying the cellular component to stop the infection from spreading. The Anti Infective Drugs Market is populated by entities (organisations, sole traders, and partnerships) that produce branded or generic anti-infective pharmaceuticals to treat microbial illnesses as well as related products and services.

Global Anti Infective Drugs Market Overview

Humans are increasingly becoming susceptible to infections as a result of the human immunodeficiency virus (HIV), which damages the immune system. If HIV is not treated in a timely manner, Acquired Immunodeficiency Syndrome (AIDS) may manifest. Around 1.5 million people worldwide contracted HIV in 2020 alone, according to The Joint United Nations Programme on HIV/AIDS (UNAIDS). HIV causes harm to or kills CD4 cells, often known as white blood cells. This interferes with the body's ability to fight disease. Antiviral medications prevent the virus from multiplying, lowering the body's level of HIV and reactivating the immune system's cell production. Another important element fueling the market's expansion is the rise in the prevalence of influenza. A contagious virus, influenza can result in both mild to moderate symptoms and serious complications, including death.

The expansion of the anti-infective drugs industry was boosted by the 35.5 million people who contracted influenza in 2018-2019, the Centres for Disease Control and Prevention (CDC) reports, which led to 490,600 hospitalisations and 34,200 fatalities. The Anti Infective Drugs Market is expected to benefit from recent advances in drug discovery methods, such as bone marrow and organ-on-chip (OOC) technology. OOCs are biometric systems that have been meticulously built to replicate the motions, movements, and physiological responses of organ systems. Target identification, validation, and screening are examples of clinical trial procedures that use OOC and stem cell technologies. These technologies are reducing the expenses associated with drug development and provide reliable predictions of medicinal efficacy and human safety.

Market expansion, however, can be constrained by high research and development costs as well as a lack of resources in healthcare facilities. However, The World Health Organisation (WHO) predicts that by 2030, one in every six people will be 60 years of age or older and that by 2050, the number of people in the world who are 60 years of age or older will have doubled (to 2.1 billion). The number of people 80 and older is expected to treble between 2020 and 2050, reaching 426 million. Age-related immune system deterioration renders the body's capacity to fight disease and respond to immunisations less effective. The immune system becomes less adept at telling self-agents apart from alien ones. T cells that retain memories of previously met antigens react less quickly to novel antigens. Due to an increase in comorbid disorders and a decline in immune system activity, people are more susceptible to infections, which is what is causing the market to grow.

Global Anti Infective Drugs Market Segmentation Analysis

The Global Anti Infective Drugs Market is segmented on the basis of Drug Type, Indication, Distribution Channel, And Geography.

Anti Infective Drugs Market, By Drug Type

• Antibiotics
• Antivirals
• Antifungals

Based on Drug Type, the market is segmented into Antibiotics, Antivirals, and Antifungals. Anti-infective medications known as antibiotics are used to treat bacterial infections. They function by either eradicating the germs or preventing them from proliferating, allowing the body's immune system to successfully combat the infection. A variety of bacterial illnesses, including those of the respiratory system, skin, urinary tract, and ears, are frequently treated with antibiotics. They come in a variety of forms, including tablets, capsules, injections, creams, and ointments.

• A class of anti-infective medication known as antiviral is used to treat viral infections. They function by concentrating on the virus and halting its reproduction and spread throughout the body. Virus diseases like the flu, herpes, HIV/AIDS, hepatitis B and C, and other viral infections are frequently treated with antivirals. Depending on the infection type being treated, they can be given orally, topically, or intravenously.

Anti Infective Drugs Market, By Indication

• HIV
• Pneumonia
• Respiratory Infections
• Tuberculosis
• Others

Based on Indication, the market is segmented into HIV, Pneumonia, Respiratory Infections, Tuberculosis, and Others. Pneumonia is an infection of the lungs that can be brought on by bacteria, viruses, fungi, or other pathogens. Anti-infective medications are used to treat pneumonia. Depending on the underlying cause of the infection, the anti-infective medication used to treat pneumonia is chosen. The initial line of therapy for bacterial pneumonia is antibiotics. They function by eliminating infection-causing germs and lowering lung inflammation. Penicillin, cephalosporins, macrolides, fluoroquinolones, and tetracyclines are a few of the typical antibiotics used to treat bacterial pneumonia.

• Antibiotics are frequently used as the first line of treatment for bacterial respiratory infections like streptococcal pharyngitis (strep throat), bacterial sinusitis, and bacterial pneumonia. The particular antibiotic administered will depend on the kind of bacteria that is infected and how susceptible it is to various medications. Penicillin, cephalosporins, macrolides, fluoroquinolones, and tetracyclines are typical antibiotics used to treat bacterial respiratory infections.

Anti Infective Drugs Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Others. Anti-infective medication is primarily distributed via hospital pharmacies. These pharmacies are in charge of obtaining, holding, dispensing, and controlling the stock of medications used to treat infections in the hospital context. Given the high prevalence of infectious disorders among hospitalised patients, anti-infective treatments are among the most often prescribed ones in hospitals.

• To ensure proper selection, dose, and administration of anti-infective medications, hospital pharmacies often collaborate closely with doctors, including infectious disease specialists and other healthcare professionals. In addition, they are in charge of keeping an eye on and handling any potential negative drug effects, interactions, and problems with drug resistance.

Anti Infective Drugs Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of The World
• On the basis of Geography, the Global Anti Infective Drugs Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The biggest market share was held by North America in 2022. In recent years, a number of reasons have contributed to an increase in the need for anti-infective medications in North America. The rising incidence of infectious diseases, notably bacterial and viral infections, in the area is one of the major contributors to this trend.
• The need for anti-infective medications has also been influenced by the ageing population and the rise in chronic illnesses including diabetes, cancer, and HIV/AIDS. The expanding prevalence of infections that are resistant to treatment is another factor influencing the increased demand for anti-infective medications in North America. To treat these infections, new and improved antibiotics and antiviral medications are now required.

Key Players

The "Global Anti Infective Drugs Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Novartis AG, Merck & Co., Inc., Alcon Pharmaceuticals Ltd., Quest Diagnostics Inc., AstraZeneca Plc., Anofi SA, GSK, Gilead Sciences, Novartis AG, and Cipla.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

Key Developments

• In August 2021, Pharmaceutical business Xellia Pharmaceuticals, which specialises in anti-infective medications, increased its Ohio production capacity. They distributed the first anti-infectives produced at the facility to US hospitals.
• In April 2021, Pfizer, a large global pharmaceutical and biotechnology company, acquired Amplyx Pharmaceuticals, Inc., a business that creates treatments for crippling and fatal illnesses and added Fosmanogepix, a novel antifungal Phase 2 candidate (APX001), to its anti-infectives portfolio. Pfizer now owns Amplyx's early-stage therapeutic portfolio, which includes antiviral (MAU868) and antifungal (APX2039) medications.
• Ace Matrix Analysis
• The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.
• Market Attractiveness
• The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Anti Infective Drugs Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.
• Porter's Five Forces
• The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behaviour of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in the Global Anti Infective Drugs Market, gauge the attractiveness of a certain sector, and assess investment possibilities.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL ANTI INFECTIVE DRUGS MARKET

• 1.1 Market Definition
• 1.2 Market Segmentation
• 1.3 Research Timelines
• 1.4 Assumptions
• 1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 2.1 Data Mining
• 2.2 Data Triangulation
• 2.3 Bottom-Up Approach
• 2.4 Top-Down Approach
• 2.5 Research Flow
• 2.6 Key Insights from Industry Experts
• 2.7 Data Sources

3 EXECUTIVE SUMMARY

• 3.1 Market Overview
• 3.2 Ecology Mapping
• 3.3 Absolute Market Opportunity
• 3.4 Market Attractiveness
• 3.5 Global Anti Infective Drugs Market Geographical Analysis (CAGR %)
• 3.6 Global Anti Infective Drugs Market, By Drug Type (USD Billion)
• 3.7 Global Anti Infective Drugs Market, By Indication (USD Billion)
• 3.8 Global Anti Infective Drugs Market, By Distribution Channel (USD Billion)
• 3.9 Future Market Opportunities
• 3.10 Global Market Split
• 3.11 Product Life Line

4 GLOBAL ANTI INFECTIVE DRUGS MARKET OUTLOOK

• 4.1 Global Anti Infective Drugs Evolution
• 4.2 Drivers
  • 4.2.1 Driver1
  • 4.2.2 Driver 2
• 4.3 Restraints
  • 4.3.1 Restraint1
  • 4.3.2 Restraint 2
• 4.4 Opportunities
  • 4.4.1 Opportunity1
  • 4.4.2 Opportunity 2
• 4.5 Porters Five Force Model
• 4.6 Value Chain Analysis
• 4.7 Pricing Analysis
• 4.8 Macroeconomic Analysis

GLOBAL ANTI INFECTIVE DRUGS MARKET, BY DRUG TYPE

• 4.9 Overview
• 4.10 Antibiotics
• 4.11 Antivirals
• 4.12 Antifungals

5 GLOBAL ANTI INFECTIVE DRUGS MARKET, BY INDICATION

• 5.1 Overview
• 5.2 HIV
• 5.3 Pneumonia
• 5.4 Respiratory Infections
• 5.5 Tuberculosis
• 5.6 Others

6 GLOBAL ANTI INFECTIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL

• 6.1 Overview
• 6.2 Hospital Pharmacies
• 6.3 Retail Pharmacies
• 6.4 Others

7 GLOBAL ANTI INFECTIVE DRUGS MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 U.K.
  • 7.3.3 France
  • 7.3.4 Italy
  • 7.3.5 Spain
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Argentina
  • 7.5.3 Rest of Latin America
• 7.6 Middle-East and Africa
  • 7.6.1 UAE
  • 7.6.2 Saudi Arabia
  • 7.6.3 South Africa
  • 7.6.4 Rest of Middle-East and Africa

8 GLOBAL ANTI INFECTIVE DRUGS MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Developments
• 8.4 Company Regional Footprint
• 8.5 Company Industry Footprint
• 8.6 ACE Matrix

9 COMPANY PROFILES

• 9.1 Novartis AG
  • 9.1.1 Company Overview
  • 9.1.2 Company Insights
  • 9.1.3 Product Benchmarking
  • 9.1.4 Key Development
  • 9.1.5 Winning Imperatives
  • 9.1.6 Current Focus & Strategies
  • 9.1.7 Threat from Competition
  • 9.1.8 SWOT Analysis
• 9.2 Merck & Co., Inc
  • 9.2.1 Company Overview
  • 9.2.2 Company Insights
  • 9.2.3 Product Benchmarking
  • 9.2.4 Key Development
  • 9.2.5 Winning Imperatives
  • 9.2.6 Current Focus & Strategies
  • 9.2.7 Threat from Competition
  • 9.2.8 SWOT Analysis
• 9.3 Alcon Pharmaceuticals Ltd
  • 9.3.1 Company Overview
  • 9.3.2 Company Insights
  • 9.3.3 Product Benchmarking
  • 9.3.4 Key Development
  • 9.3.5 Winning Imperatives
  • 9.3.6 Current Focus & Strategies
  • 9.3.7 Threat from Competition
  • 9.3.8 SWOT Analysis
• 9.4 Quest Diagnostics Inc.
  • 9.4.1 Company Overview
  • 9.4.2 Company Insights
  • 9.4.3 Product Benchmarking
  • 9.4.4 Key Development
  • 9.4.5 Winning Imperatives
  • 9.4.6 Current Focus & Strategies
  • 9.4.7 Threat from Competition
  • 9.4.8 SWOT Analysis
• 9.5 AstraZeneca Plc
  • 9.5.1 Company Overview
  • 9.5.2 Company Insights
  • 9.5.3 Product Benchmarking
  • 9.5.4 Key Development
  • 9.5.5 Winning Imperatives
  • 9.5.6 Current Focus & Strategies
  • 9.5.7 Threat from Competition
  • 9.5.8 SWOT Analysis
• 9.6 Anofi SA
  • 9.6.1 Company Overview
  • 9.6.2 Company Insights
  • 9.6.3 Product Benchmarking
  • 9.6.4 Key Development
  • 9.6.5 Winning Imperatives
  • 9.6.6 Current Focus & Strategies
  • 9.6.7 Threat from Competition
  • 9.6.8 SWOT Analysis
• 9.7 GSK
  • 9.7.1 Company Overview
  • 9.7.2 Company Insights
  • 9.7.3 Product Benchmarking
  • 9.7.4 Key Development
  • 9.7.5 Winning Imperatives
  • 9.7.6 Current Focus & Strategies
  • 9.7.7 Threat from Competition
  • 9.7.8 SWOT Analysis
• 9.8 Gilead Sciences
  • 9.8.1 Company Overview
  • 9.8.2 Company Insights
  • 9.8.3 Product Benchmarking
  • 9.8.4 Key Development
  • 9.8.5 Winning Imperatives
  • 9.8.6 Current Focus & Strategies
  • 9.8.7 Threat from Competition
  • 9.8.8 SWOT Analysis
• 9.9 Novartis AG
  • 9.9.1 Company Overview
  • 9.9.2 Company Insights
  • 9.9.3 Product Benchmarking
  • 9.9.4 Key Development
  • 9.9.5 Winning Imperatives
  • 9.9.6 Current Focus & Strategies
  • 9.9.7 Threat from Competition
  • 9.9.8 SWOT Analysis
• 9.10 Cipla
  • 9.10.1 Company Overview
  • 9.10.2 Company Insights
  • 9.10.3 Product Benchmarking
  • 9.10.4 Key Development
  • 9.10.5 Winning Imperatives
  • 9.10.6 Current Focus & Strategies
  • 9.10.7 Threat from Competition
  • 9.10.8 SWOT Analysis

10 VERIFIED MARKET INTELLIGENCE

• 10.1 About Verified Market Intelligence
• 10.2 Dynamic Data Visualization